Catalog No.: PC-43167Not For Human Use, Lab Use Only.
SCR7 is a specific inhibitor of nonhomologous end-joining (NHEJ), blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I.
SCR7 is a specific inhibitor of nonhomologous end-joining (NHEJ), blocks DNA Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I.
SCR7 inhibits NHEJ in a Ligase IV-dependent manner within cells, causes accumulation of double-strand breaks (DSBs), and activates the intrinsic apoptotic pathway; decreases cell proliferation of MCF7, A549, and HeLa with IC50 of 40, 34, and 44 uM, respectively.
SCR7 increases the efficacy of DSB-inducing therapeutic modalities in mouse xenografts.
SCR7 increases the efficiency of precise genome editing with CRISPR-Cas9 in mammalian cell lines and in mice.
